Yes, this is sadly correct. In the pharma industry, we call it pleasing "the stakeholders." Many times more expensive tests/treatments/etc are developed over cheaper ones, as the risk seemingly (if the MBA stakeholders are to be believed) necessitates chasing medical innovations that will have the largest ROI.